# OSU as a Network Lead Academic Participating Site for the NCI NCTN

> **NIH NIH UG1** · OHIO STATE UNIVERSITY · 2021 · $1,238,889

## Abstract

PROJECT SUMMARY
The goal of this application is to provide the infrastructure to support The Ohio State University's (OSU)
participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead
Academic Participating Site (OSU-LAPS). Faculty from OSU are integrated into the scientific and administrative
activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing
adult NCTN network groups using OSU Comprehensive Cancer Center (OSUCCC) resources to leverage group
resources. OSUCCC investigators develop and lead studies designed to enroll patients on multi-disciplinary
treatment trials as well as develop and perform correlative science related research studies, bringing special
expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation
oncologists, transplanters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory
scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame
the clinical and basic science questions whose answers contribute to improved patient outcomes and to
understanding tumor biology. OSU-LAPS will offer innovative NCI trials to the OSU patient population, support
scientific discoveries about tumor biology, find better treatments, and augment the quality of life for patients thus
improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1)
investigate new therapeutic agents, and their toxicities in Phase I to III NCI clinical trials; 2) evaluate the efficacy
and toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively;
3) develop multi-modal approaches using surgical, immunological, and radiotherapeutic therapies in optimal
combinations; 4) integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and
biostatistics in the design and execution of therapeutic protocols; 5) improve cancer outcomes through discovery
and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) understand
and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) improve the management of
cancer related symptoms, 8) form the next generation of clinical investigators by offering them formal teaching
and mentoring within the NCTN, and 9) enroll volunteering patients on trials.

## Key facts

- **NIH application ID:** 10112201
- **Project number:** 5UG1CA233331-03
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** DAVID P. CARBONE
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,238,889
- **Award type:** 5
- **Project period:** 2019-03-28 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10112201

## Citation

> US National Institutes of Health, RePORTER application 10112201, OSU as a Network Lead Academic Participating Site for the NCI NCTN (5UG1CA233331-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10112201. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*